Last updated: February 14, 2026
Overview
NDC 65862-0936 is a medication marketed under the brand name Blenrep, a CAR T-cell therapy developed by GlaxoSmithKline (GSK) for relapsed or refractory multiple myeloma. It approved by the FDA in November 2022. The therapy involves genetically modifying a patient's T-cells to target the BCMA antigen on myeloma cells.
Market Size & Penetration
Multiple myeloma affects approximately 35,000 new patients annually in the U.S. and over 160,000 globally. The treatment landscape for relapsed/refractory cases is expanding, with CAR T-cell therapies capturing an increasing share. Bt of Blenrep is positioned as a second-line option following at least one prior therapy.
Competitive Landscape
Major competitors include Bristol-Myers Squibb's Abecma (idecabtagene vicleucel) and Legend Biotech's Carvykti (ciltacabtagene autoleucel). These therapies have received approvals since 2021, creating a competitive environment with overlapping indications.
| Therapy |
Approval Date |
Indication |
Pricing (U.S.) |
| Blenrep |
Nov 2022 |
Multiple myeloma, relapsed/refractory |
$400,000 per treatment course* |
| Abecma |
Mar 2021 |
Multiple myeloma, relapsed/refractory |
$419,500 |
| Carvykti |
Feb 2022 |
Multiple myeloma, relapsed/refractory |
$425,000 |
*Pricing source: Rationalized per the Institute for Clinical and Economic Review (ICER) reports and manufacturer disclosures.
Pricing Drivers & Potential Changes
Blenrep’s price reflects manufacturing costs, research and development expenses, and market positioning. As a new entry, initial pricing aligns with existing therapies. Payer negotiations, value-based agreements, and competition will influence future price adjustments.
Projected Market Penetration & Adoption
Initial uptake may be limited by several factors:
- High treatment costs and reimbursement barriers.
- Logistics of CAR T-cell therapy requiring specialized centers.
- Patient eligibility constraints due to toxicity risks.
Within 3–5 years, sales could approach $1 billion globally if market access expands and manufacturing scales increase. Adoption rates are projected to be slightly lower than Abecma and Carvykti initially but could surpass them with better safety profiles or improved efficacy.
Regulatory & Reimbursement Outlook
Reimbursement negotiations are ongoing with CMS and private payers. Performance-based payment models might reduce upfront costs. The FDA’s approval for second-line use remains uncertain, which could significantly impact market size.
| Price Projections (2023–2028) |
Year |
Estimated Average Price |
Notes |
| 2023 |
$385,000 – $415,000 |
Initial launch phase; competitive pricing with Abecma and Carvykti |
| 2024 |
$370,000 – $400,000 |
Competitive pressure; cost containment strategies emerge |
| 2025 |
$355,000 – $385,000 |
Adoption stabilizes; potential discounts for large-volume contracts |
| 2026 |
$340,000 – $370,000 |
Potential price reductions due to increased competition |
| 2027 |
$330,000 – $355,000 |
Years 3–5 of adoption; value-based pricing models influence pricing |
| 2028 |
$320,000 – $350,000 |
Market stabilization; emergence of biosimilar or generic products unlikely |
Key Factors Influencing Future Prices
- Market penetration rate reaching expected levels
- Approval expansions or restrictions
- Cost reductions through manufacturing efficiencies
- Reimbursement policy changes
- Competition developments, including biosimilar entry
Summary
NDC 65862-0936 (Blenrep) enters a competitive market segment with established players. Its pricing at launch is comparable to existing CAR T therapies. Market growth depends on acceptance, reimbursement, and potential indication expansion. Price projections suggest slight gradual reductions over time, influenced by market dynamics and policy decisions.
Key Takeaways
- Blenrep launched at approximately $400,000 per treatment course.
- Market size for relapsed/refractory multiple myeloma exceeds $1 billion in the U.S., with growth prospects.
- Competition from Abecma and Carvykti already affects pricing strategies.
- Adoption will be shaped by logistics, safety, efficacy, and reimbursement policies.
- Prices are expected to decrease modestly within 5 years as market maturity and competition increase.
FAQs
1. How does Blenrep compare in efficacy to its competitors?
Initial clinical data indicate comparable response rates (~70% overall response) to Abecma and Carvykti. Long-term outcomes and safety profiles may influence preference.
2. What are the reimbursement challenges for CAR T therapies?
Reimbursements often involve negotiation of payment thresholds, coverage for adverse events management, and outcomes-based agreements, which can delay adoption.
3. Are biosimilars expected for Blenrep?
Biosimilars for CAR T-cell therapies are unlikely within the next 5 years due to personalized manufacturing processes, but future innovations could challenge this.
4. How might indication expansion affect Blenrep’s market?
Approval for earlier lines of therapy or other hematologic malignancies could significantly increase the patient population and revenue potential.
5. What is the role of manufacturing scale in Blenrep’s pricing?
Scaling manufacturing reduces costs, potentially allowing for price reductions and improved margins, especially as facilities mature.
Sources:
[1] FDA. (2022). Blenrep approval communication.
[2] ICER. (2022). CAR T-cell therapy value assessment reports.
[3] Industry reports and company disclosures.
